GSTO1*C/GSTO2*G haplotype is associated with risk of transitional cell carcinoma of urinary bladder

Abstract

Our results indicate that GSTO1*C/GSTO2*G haplotype is associated with increased risk of TCC. The modifying effect of GSTO2*G/G genotype on individual susceptibility to TCC is more pronounced, when associated with smoking.

Polymorphisms in Genes Encoding Glutathione Transferase Pi and Glutathione Transferase Omega Influence Prostate Cancer Risk and Prognosis

“…Our results showed that homozygous carriers of GSTO1*A/A variant genotypes are at increased risk of PC, which is in agreement with another urological cancer, clear cell renal cell carcinoma. Our data on the association of GSTO2*G variant allele with increased risk of PC are in line with previous findings on ovarian (Pongstaporn et al, 2006), breast (Xu et al, 2014), bladder (Djukic et al, 2015), and clear cell renal cell carcinoma (Radic et al, 2018). Moreover, as a result of LD found between these SNPs, carriers of H2 haplotype, consisting of both GSTO1*A and GSTO2*G variant alleles, had significantly increased risk of PC.…”

Association of glutathione transferase omega polymorphisms with risk and survival in transitional cell carcinoma of urinary bladder

“…We further assessed the effects of GSTO1/GSTO2 haplotypes on TCC risk, based on the linkage disequilibrium found for GSTO1 (rs4925) and GSTO2 (rs156697). The study subjects with GSTO1*C/GSTO2*G (GSTO1 wild type/ GSTO2 variant) haplotype were at the highest risk for the development of transitional cell carcinoma of urinary bladder (OR = 2.8, p = 0.002) [38].…”

The Polymorphisms in GSTO Genes (GSTO1 rs4925, GSTO2 rs156697, and GSTO2 rs2297235) Affect the Risk for Testicular Germ Cell Tumor Development: A Pilot Study

“…Their polymorphic expression may diminish their catalytic properties and take a toll on their antioxidant protection capacities. In the case of GSTO isoenzymes, three particular polymorphisms ( GSTO1 rs4925, GSTO2 rs156697, and GSTO2 rs2297235; Supplementary Figure S1 ) have been investigated in various clinical scenarios, especially as new perspective candidates for risk biomarkers in the field of urologic oncology [ 22 , 23 , 24 , 25 , 26 ]. Indeed, the widely assessed polymorphisms are associated with their reduced reduction activity, as GSTO1 single nucleotide polymorphism ( GSTO1 *C419A (rs4925)) affects the deglutathionylase and thioltransferase activity.…”

“…As reactive species may set an ambient for cancer onset and evolution, the redox status of still very young male individuals could be additionally characterized by perturbations due to reduced antioxidant activities of GSTO isoenzymes. Several polymorphisms in the GST omega class have been acknowledged as cancer-risk biomarkers [ 22 , 23 , 24 , 25 ], but, to the best of our knowledge, this is the first study investigating the association of GSTO1 polymorphic expression in relation to testicular tumorigenesis [ 31 , 32 , 33 , 34 , 35 ]. Therefore, the aim of this pilot study was to further define a unique redox profile by determining the individual, combined, haplotype, and cumulative effect of GSTO1 rs4925, GSTO2 rs156697, and GSTO2 rs2297235 genetic variants on the risk for testicular germ cell tumor development.…”